• 1. Exceptionally high temperature spin crossover in amide-functionalised 2,6-bis(pyrazol-1-yl)pyridine iron(ii) complex revealed by variable temperature Raman spectroscopy and single crystal X-ray diffraction?
  Max Attwood,Hiroki Akutsu,Lee Martin,Toby J. Blundell,Pierre Le Maguere,Scott S. Turner Dalton Trans., 2021,50, 11843-11851
• 2. Estimation of hydrogen sulfide from crude petroleum: a unique invention using a simple chemosensor?
  Shampa Kundu,Prithidipa Sahoo New J. Chem., 2019,43, 12369-12374
• 3. Distribution and ecological risk assessment of typical antibiotics in the surface waters of seven major rivers, China?
  Environ. Sci.: Processes Impacts, 2021,23, 1088-1100
• 4. Fe3O4/FeS2 heterostructures enable efficient oxygen evolution reaction?
  Xingqun Zheng,Lele Song,Xin Feng,Li Li,Zidong Wei J. Mater. Chem. A, 2020,8, 14145-14151
• 5. Enantiomorphic symmetry breaking in crystallization of molten sodium chlorate?
  Martin R. Ward,Gary W. Copeland,Andrew J. Alexander Chem. Commun., 2010,46, 7634-7636

Introduction to N4,N4-Dimethyl-5-phenylpyrimidine-2,4-diamine (CAS No. 320424-61-1)

N4,N4-Dimethyl-5-phenylpyrimidine-2,4-diamine is a specialized organic compound that has garnered significant attention in the field of pharmaceutical chemistry and medicinal research. This compound, identified by its Chemical Abstracts Service (CAS) number 320424-61-1, belongs to the pyrimidine derivatives family, a class of molecules widely recognized for their diverse biological activities and therapeutic potential. The structural framework of this compound incorporates a pyrimidine core substituted with dimethyl and phenyl groups, as well as amino functionalities at the 2 and 4 positions, which contribute to its unique chemical properties and reactivity.

The synthesis and characterization of N4,N4-Dimethyl-5-phenylpyrimidine-2,4-diamine have been subjects of extensive studies due to its promising applications in drug discovery. The pyrimidine scaffold is a fundamental motif in many bioactive molecules, including nucleoside analogs and kinase inhibitors. The presence of the dimethyl groups at the 4-position enhances the steric bulk of the molecule, potentially influencing its binding affinity and selectivity towards biological targets. Additionally, the phenyl substituent at the 5-position introduces hydrophobic interactions and may modulate the compound's solubility and metabolic stability.

Recent advancements in computational chemistry and molecular modeling have enabled researchers to predict the binding modes of N4,N4-Dimethyl-5-phenylpyrimidine-2,4-diamine with various protein targets. These studies suggest that the compound may interact with enzymes involved in cellular signaling pathways, such as tyrosine kinases and DNA repair mechanisms. The amino groups at the 2 and 4 positions provide opportunities for further functionalization, allowing for the development of derivatives with enhanced pharmacological properties.

In vitro experiments have demonstrated that N4,N4-Dimethyl-5-phenylpyrimidine-2,4-diamine exhibits inhibitory activity against certain cancer cell lines. The compound's ability to disrupt key cellular processes has led to its investigation as a potential candidate for anticancer therapy. Furthermore, its structural similarity to known antiviral agents has prompted research into its efficacy against viral infections. The combination of these properties makes N4,N4-Dimethyl-5-phenylpyrimidine-2,4-diamine a compelling subject for further exploration in medicinal chemistry.

The development of novel synthetic methodologies has been crucial in facilitating the production of N4,N4-Dimethyl-5-phenylpyrimidine-2,4-diamine on a scalable basis. Modern synthetic routes often involve multi-step organic transformations, including condensation reactions, cyclization processes, and selective functional group modifications. These methods ensure high yields and purity, which are essential for preclinical and clinical studies. The optimization of synthetic protocols has also enabled the preparation of enantiomerically pure forms of the compound, which is critical for evaluating its stereochemical specificity.

The pharmacokinetic profile of N4,N4-Dimethyl-5-phenylpyrimidine-2,4-diamine is another area of active investigation. Understanding how the compound is absorbed, distributed, metabolized, and excreted (ADME) is essential for determining its therapeutic window and potential side effects. Advanced analytical techniques, such as high-performance liquid chromatography (HPLC) and mass spectrometry (MS), have been employed to study these processes in detail. These studies provide valuable insights into the compound's behavior within biological systems and inform drug design strategies.

Preclinical trials have been conducted to assess the safety and efficacy of N4,N4-Dimethyl-5-phenylpyrimidine-2,4-diamine in animal models. These trials have revealed promising results regarding its anti-proliferative effects on tumor cells while maintaining acceptable levels of toxicity. The findings from these studies have laid the groundwork for potential human clinical trials aimed at evaluating its therapeutic potential in patients with specific diseases. Collaborative efforts between academic institutions and pharmaceutical companies are increasingly focused on translating laboratory discoveries into viable treatments.

The role of N4,N4-Dimethyl-5-phenylpyrimidine-2,4-diamine in combination therapies is also being explored. By pairing this compound with other drugs or therapeutic agents, researchers aim to enhance treatment outcomes through synergistic effects. Such combinations may improve drug resistance management and reduce adverse reactions associated with single-agent therapies. The development of combination strategies represents a significant advancement in personalized medicine approaches.

The future directions for research on N4,N4-Dimethyl-5-phenylpyrimidine-2,4-diamine include exploring its mechanisms of action at a molecular level. Techniques such as X-ray crystallography and nuclear magnetic resonance (NMR) spectroscopy are being utilized to elucidate how this compound interacts with biological targets. Additionally, computational modeling techniques are being refined to predict how structural modifications will affect its biological activity. These efforts are expected to accelerate the discovery of novel derivatives with improved pharmacological profiles.

The regulatory landscape surrounding new pharmaceutical compounds like N4,N4-Dimethyl-5-phenylpyrimidine-2,4-diamine is stringent but essential for ensuring patient safety and efficacy. Regulatory agencies require comprehensive data from preclinical studies before approving human trials can commence. Once clinical trials are underway, rigorous monitoring is conducted to track adverse events and assess treatment benefits accurately. Compliance with regulatory guidelines is critical for advancing promising compounds through each stage of development.

In conclusion,N4,N4-Dimethyl-5-phenoypyrimidine - 2 , - diamino ( CAS No . 320 - 42 - -61 -1 ) represents an exciting avenue in pharmaceutical research due to its structural features , biological activities , p >

• 771555-68-1(2-Chloro-N,N-dimethyl-5-phenylpyrimidin-4-amine)
• 155999-32-9(2,4-Pyrimidinediamine, N,N,N',N',6-pentamethyl-5-(3-methylphenyl)-)
• 71552-29-9(5-(4-Aminophenyl)-2,4-pyrimidinediamine)
• 18588-49-3(5-phenylpyrimidine-2,4-diamine)
• 60122-84-1(N-benzyl-5-phenylpyrimidin-4-amine)
• 575475-06-8(2,4-Pyrimidinediamine, N,N'-bis([1,1'-biphenyl]-2-yl)-5-methyl-)
• 28458-75-5(2,4-PYRIMIDINEDIAMINE, N,N,N',N',5-PENTAMETHYL-)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)